Stocklytics Platform
Asset logo for symbol VTRS
Viatris
VTRS60
$12.280.00%$12.28
S&P500
Asset logo for symbol VTRS
VTRS60

$12.28

0.00%
Key Stats
Open$12.30
Prev. Close$0.00
EPS-0.73
Next Earnings DateMar 14, 2025
PE Ratio-
LOWHIGH
Day Range12.28
12.40
52 Week Range8.74
13.62
Ratios
Revenue-
EPS-0.73
Fundamentals
Payout Ratio-
Industry average yield2.90%
Last Dividend pay dateDec 13, 2024

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

VTRS-
US Healthcare Sector-
US Market-
warning

VTRS / Market

VTRS lose to the US Market which returned 1926.57% over the last twenty four hours.
warning

VTRS / Healthcare Sector

VTRS lose to the US Healthcare sector which returned 208.54% over the last twenty four hours.

Viatris (VTRS) Statistics

Viatris Inc, formerly known as Mylan Inc, is a global pharmaceutical company that specializes in the development, manufacturing, and marketing of generic and branded drugs. The company was formed through a merger between Mylan and Upjohn, the off-patent branded and generic established medicines business of Pfizer Inc. Viatris operates in more than 165 countries and has a diverse portfolio of over 1,400 products across various therapeutic categories.
With a market capitalization of over $15 billion, Viatris is considered a mid-cap stock. As of the latest available data, the stock is trading at a price-to-earnings ratio of around 7.5, which indicates that it may be undervalued compared to the broader market. The company's stock has experienced some volatility in recent years, but has shown potential for growth.
add Viatris  to watchlist

Keep an eye on Viatris

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Viatris (VTRS) stock's performance compared to its sector and the market over the past year?

Over the past year, Viatris (VTRS) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 25.30%, Viatris has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 47.39%, it has fallen short of the market average. This comparison highlights Viatris 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Viatris (VTRS) stock?

The PE ratio for Viatris (VTRS) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Viatris (VTRS) stock?

The Earnings Per Share (EPS) for Viatris (VTRS), calculated on a diluted basis, is -$0.73. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Viatris (VTRS) stock?

The operating margin for Viatris (VTRS) is 13.88%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Viatris (VTRS) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Viatris (VTRS) is $2.89B. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Viatris (VTRS) have?

Viatris (VTRS) has a total debt of $16.01B. The net debt, which accounts for cash and cash equivalents against the total debt, is $15.74B.

Take Your Investments to a Whole New Level